查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1840723

鐮狀細胞性貧血檢測和篩檢市場（按檢測類型、產品、最終用戶、樣本類型和分銷管道）—全球預測 2025-2032

Sickle Cell Anemia Testing & Screening Market by Test Type, Product, End User, Sample Type, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年鐮狀性貧血檢測和篩檢市場將成長至 30.3 億美元，複合年成長率為 13.90%。

主要市場統計數據
基準年2024年 10.7億美元
預計2025年 12.1億美元
預測年份：2032年 30.3億美元
複合年成長率（%） 13.90%

為醫療保健領導者提供關於鐮狀性貧血診斷重點、技術促進因素、臨床工作流程影響和相關人員決策的策略入門指南

鐮狀細胞性貧血檢測處於診斷創新、公共衛生重點和不斷發展的臨床實踐的交匯點。以下介紹概述了當代檢測現狀、推動對準確及時診斷需求的臨床需求，以及影響醫療機構技術應用的策略性考量。本文重點介紹了檢測設計、樣本處理和數據解讀的進步如何重塑診斷工作流程，同時回應了日益成長的人口健康篩檢需求意識。

臨床醫生和實驗室負責人面臨著提高診斷準確性、縮短週轉時間和控制成本的雙重壓力。因此，檢測方法的選擇越來越依賴於在分析性能與適用性、監管透明度和供應鏈彈性之間取得平衡。同時，研究機構和生物技術開發者正在挑戰分子和高解析度技術的極限，以實現更早的檢測和更詳細的基因表徵。因此，相關人員必須應對快速變化的生態系統，在這個生態系統中，臨床效用、擴充性以及與電子醫療系統的整合決定了長期價值。

本介紹為深入探討變革性市場變化、關稅影響、細分市場細微差別、區域動態、企業行為和可行建議奠定了基礎。它強調了將技術創新與切實可行的實施策略相結合的重要性，以改善患者治療效果並最佳化不同醫療環境中的資源利用率。

技術融合、護理路徑重新設計、勞動力技能轉變以及夥伴關係主導的交付如何重塑鐮狀細胞性貧血的檢測和篩檢實踐

由於技術日趨成熟、診斷途徑的重構以及對人群篩檢的日益重視，鐮狀細胞性貧血的檢測領域正在發生重大變化。新型分子檢測和次世代定序方法補充了傳統的基於蛋白質的方法，使臨床醫生能夠將基因型分析與表現型評估相結合，從而獲得更全面的診斷結果。同時，側流免疫檢測和自動化分析儀的創新正在降低分散式檢查的門檻，擴大門診病人和社區環境中的檢測可及性。

在營運方面，實驗室正在採用更模組化的工作流程，並將用於變異分離的高效液相層析與分子確認檢測相結合，從而在提高診斷確定性的同時簡化了通量。數位化結果管理與電子醫療系統的互通性的整合正在加速臨床決策支持，使護理團隊能夠更快地根據陽性觀察採取行動。同時，支付方和公共衛生計畫正在重新調整檢測途徑，以強調新生兒和產前篩檢、早期療育以及與護理的聯繫，從而產生了對可大規模部署的標準化、高品質檢測的需求。

最後，競爭格局正在轉向設備製造商、耗材供應商和服務供應商合作提供端到端解決方案。這些策略夥伴關係關係旨在減少部署摩擦，增強客戶支持，並擴展培訓資源，促進先進診斷方法在醫療機構的廣泛應用。

評估 2025 年美國關稅政策變化對鐮狀細胞檢測供應鏈的多方面營運、供應鏈和策略影響

美國宣布的2025年關稅調整對鐮狀性貧血檢測所用診斷設備、試劑和輔助耗材的整個供應鏈產生了複雜的下游影響，實驗室和經銷商正在重新審視其供應商關係，以降低進口成本上升的風險。因此，採購團隊正在多元化其供應商組合，尋求更近的生產地點，並協商長期契約，以穩定投入的可用性和價格的可預測性。

在產品層面，關稅正在影響製造商對生產地點和全球分銷結構的決策。一些公司正在加快對國內或區域製造能力的投資，以緩解關稅相關的脆弱性，而其他公司則正在最佳化材料清單和包裝，以降低關稅分類風險。這些策略性因應措施，加上對供應鏈透明度和庫存緩衝的日益重視，共同影響前置作業時間、營運成本需求和產品上市時間。

在臨床方面，雖然檢測的基本績效特徵將保持不變，但隨著相關人員努力協調採購並控制成本，引入新平台和耗材的時間表可能會延長。政策制定者和行業協會正在積極與監管機構和貿易官員溝通，以澄清關稅解釋，並倡導對基本醫療用品實施豁免和分階段引入。同時，實驗室和衛生系統正在採取緩解策略，例如整合訂單、利用集團採購組織以及擴展本地校準和維護能力，以在不斷變化的貿易條件下保持服務的連續性。

細粒度細分分析揭示了測試模式、產品系列、最終用戶資料、樣本模式和管道策略如何相互作用以影響診斷採用

了解市場細分可以揭示檢測技術、產品系列、最終用戶、樣本類型和分銷通路如何影響其應用和服務。依檢測類型分類，包括高效液相層析、免疫測量和分子檢測法，包括用於免疫測量酵素結合免疫吸附檢測法(ELSA) 和側流分析法，以及用於分子檢測的次世代定序儀和聚合酵素鏈鎖反應平台。每種檢測方法在分析深度、通量和易用性方面都有各自的優缺點，這會影響它們在醫療保健環境中的部署位置和方式。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 在分散的醫療環境中整合新生兒護理照護現場新生兒篩檢工具
  • 採用高通量基因組定序工作流程對新生兒進行早期帶因者檢測
  • 引進人工智慧模式識別軟體，在篩檢測試中區分鐮狀細胞特徵
  • 實施基於 CRISPR 的分子檢測，以準確檢測鐮狀鐮狀細胞基因變異
  • 使用智慧型手機比色法擴大農村地區鐮狀細胞疾病篩檢的覆蓋範圍
  • 擴大撒哈拉以南非洲地區衛生系統的強制性新生兒鐮狀細胞疾病篩檢項目
  • 開發整合電子健康記錄系統，將篩檢結果與病患照護路徑連結起來
  • 新生兒篩檢陽性後遠距遺傳諮詢遠端醫療平台的構建
  • 透過政府機構和私人實驗室的合作，支持社區的鐮狀細胞篩檢工作

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

鐮狀性貧血檢測與篩檢市場（依檢測類型）

  • 高效液相層析
  • 免疫檢測
    • 酵素結合免疫吸附試驗
    • 橫向流動
  • 分子檢測
    • 次世代定序
    • 聚合酵素鏈鎖反應

鐮狀細胞性貧血檢測和篩檢市場（按產品）

  • 耗材
    • 套件
    • 試劑
  • 裝置
    • 高效液相層析系統
    • 免疫檢測分析儀
    • 分子診斷平台
  • 服務
    • 維護和支援
    • 培訓和諮詢

鐮狀性貧血檢測與篩檢市場（依最終用戶）

  • 診斷實驗室
    • 醫院實驗室
    • 獨立實驗室
  • 醫院和診所
    • 私人診所
    • 公立醫院
  • 研究機構
    • 學術機構
    • 政府研究中心

鐮狀性貧血檢測與篩檢市場（依樣本類型）

  • 血液樣本
    • 微血管血
    • 靜脈血
  • 唾液樣本
    • 收集套件
    • 直接收集

鐮狀細胞性貧血檢測與篩檢市場（依通路）

  • 直接地
    • 公司自有銷售隊伍
  • 間接地
    • 經銷商
    • 網路零售

鐮狀細胞性貧血檢測與篩檢市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

鐮狀細胞性貧血檢測與篩檢市場（依群體）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

鐮狀性貧血檢測和篩檢市場（按國家/地區）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • F. Hoffmann-La Roche Ltd
    • Abbott Laboratories
    • Thermo Fisher Scientific Inc.
    • Bio-Rad Laboratories, Inc.
    • Becton, Dickinson and Company
    • Siemens Healthineers AG
    • DiaSorin SpA
    • PerkinElmer, Inc.
    • Ortho Clinical Diagnostics, Inc.
    • QIAGEN NV
Product Code: MRR-A339DAEFA37A

The Sickle Cell Anemia Testing & Screening Market is projected to grow by USD 3.03 billion at a CAGR of 13.90% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.07 billion
Estimated Year [2025] USD 1.21 billion
Forecast Year [2032] USD 3.03 billion
CAGR (%) 13.90%

A strategic primer on sickle cell anemia diagnostic priorities, technological drivers, clinical workflow implications, and stakeholder decision imperatives for healthcare leaders

Sickle cell anemia testing is at the intersection of diagnostic innovation, public health priorities, and evolving clinical practice. The introduction below frames the contemporary testing landscape, the clinical imperatives driving demand for accurate and timely diagnosis, and the strategic considerations shaping technology adoption across healthcare settings. It emphasizes how advances in assay design, sample handling, and data interpretation are reconfiguring diagnostic workflows while responding to increasing awareness of population health screening needs.

Clinicians and laboratory leaders face simultaneous pressures to improve diagnostic accuracy, shorten turnaround times, and manage costs. As a result, test selection increasingly balances analytical performance with operational compatibility, regulatory clarity, and supply chain resilience. In parallel, research institutions and biotechnology developers are pushing the envelope on molecular and high-resolution techniques to enable earlier detection and deeper genetic characterization. Consequently, stakeholders must navigate a rapidly changing ecosystem where clinical utility, scalability, and integration with electronic health systems determine long-term value.

This introduction sets the stage for a deeper exploration of transformative market shifts, tariff impacts, segmentation nuances, regional dynamics, corporate behaviors, and actionable recommendations. It underscores the importance of aligning technical innovation with pragmatic implementation strategies to improve patient outcomes and optimize resource use across diverse care environments.

How technological convergence, care pathway redesign, workforce skill shifts, and partnership-driven offerings are reshaping sickle cell anemia testing and screening practices

The landscape of sickle cell anemia testing is undergoing transformative shifts driven by technological maturation, diagnostic pathway reengineering, and a stronger focus on population-level screening. Emerging molecular assays and next-generation sequencing approaches are complementing traditional protein-based methods, enabling clinicians to combine genotypic insight with phenotypic assessment for more comprehensive diagnostic clarity. Concurrently, innovations in lateral flow immunoassays and automated analyzers are lowering barriers to decentralized testing, expanding access in outpatient and community settings.

Operationally, laboratories are adopting more modular workflows that integrate high-performance liquid chromatography for variant separation with molecular confirmatory testing, which improves diagnostic certainty while streamlining throughput. The integration of digital result management and interoperability with electronic health systems is accelerating clinical decision support, enabling care teams to act sooner on positive findings. At the same time, payers and public health programs are recalibrating testing pathways to emphasize newborn and prenatal screening, early intervention, and linkage to care, creating demand for standardized, high-quality tests that can be deployed at scale.

Finally, the competitive landscape is shifting toward collaborations between instrument manufacturers, consumable suppliers, and service providers to deliver end-to-end solutions. These strategic partnerships aim to reduce implementation friction, enhance customer support, and expand training resources, thereby facilitating broader adoption of advanced diagnostic modalities across varied care settings.

Assessing the multifaceted operational, supply chain, and strategic repercussions of United States tariff policy changes in 2025 on sickle cell testing supply chains

United States tariff adjustments announced for 2025 have introduced a complex set of downstream effects across the supply chain for diagnostic instruments, reagents, and ancillary consumables used in sickle cell anemia testing. The immediate operational impact centers on procurement cycles and supplier selection, as laboratories and distributors reassess vendor relationships to mitigate exposure to increased import costs. As a consequence, procurement teams are diversifying supplier portfolios, seeking nearer-shore manufacturing, and negotiating longer-term contracts to stabilize input availability and price predictability.

At the product level, tariffs are influencing manufacturers' decisions about where to locate production and how to structure global distribution. Some firms are accelerating investments in domestic or regional manufacturing capacity to reduce tariff-related vulnerability, while others are optimizing bill-of-materials and packaging to lessen tariff classification risk. These strategic responses are coupled with increased emphasis on supply chain transparency and inventory buffering, which collectively affect lead times, working capital requirements, and the cadence of product launches.

Clinically, while the fundamental performance characteristics of tests remain unchanged, implementation timelines for new platforms and consumables can be extended as stakeholders navigate procurement adjustments and cost-containment initiatives. Policymakers and industry associations are actively engaging with regulators and trade officials to clarify tariff interpretation and to advocate for exemptions or phased implementation for essential medical goods. In parallel, laboratories and health systems are adopting mitigation tactics such as consolidating orders, leveraging group purchasing organizations, and expanding local calibration and maintenance capabilities to preserve service continuity amid evolving trade conditions.

Granular segmentation analysis revealing how test modalities, product portfolios, end user profiles, sample modalities, and channel strategies interact to influence diagnostic adoption

Understanding market segmentation provides clarity on how testing technologies, product portfolios, end users, sample types, and distribution pathways collectively shape adoption and service delivery. Based on test type, the landscape is composed of high performance liquid chromatography, immunoassay, and molecular assay approaches, with immunoassay options spanning enzyme linked immunosorbent assay and lateral flow formats, and molecular assay choices including next generation sequencing and polymerase chain reaction platforms. Each test family delivers distinct trade-offs between analytical depth, throughput, and ease of use, which influence where and how they are implemented across care settings.

Based on product, offerings are differentiated as consumables, instruments, and services. Consumables encompass kits and reagents that are the recurring elements of testing workflows; instruments include HPLC systems, immunoassay analyzers, and molecular diagnostic platforms that determine throughput and integration complexity; and services cover maintenance and support as well as training and consultancy necessary to ensure technical competence and operational continuity. The balance among these product pillars informs cost structures and supplier value propositions.

Based on end user, deployment spans diagnostic laboratories, hospitals and clinics, and research institutes. Diagnostic laboratories further bifurcate into hospital based labs and independent labs, hospitals and clinics divide into private clinics and public hospitals, and research institutes include academic institutions and government research centers. Based on sample type, testing workflows rely on blood samples and saliva samples, with blood subdivided into capillary blood and venous blood and saliva broken into collection kits and direct collection methods, each affecting sample integrity and collection logistics. Finally, based on distribution channel, products reach users via direct and indirect channels, where direct engagement is typified by a company owned sales force and indirect routes employ distributors and online retail, creating different service expectations and commercialization dynamics.

Regional dynamics and differentiated adoption pathways across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence diagnostic deployment and strategic planning

Regional dynamics shape adoption patterns, regulatory pathways, and investment priorities for sickle cell anemia testing in meaningful ways. In the Americas, established clinical networks and newborn screening infrastructure support widespread use of established assay platforms, while innovation is concentrated around integrating molecular confirmation into routine workflows and expanding community-based screening programs. Health systems in this region also place higher emphasis on reimbursement alignment and value demonstration, which affects how novel technologies are introduced into clinical practice.

In Europe, the Middle East and Africa, heterogeneous regulatory frameworks and variable healthcare infrastructure produce a mosaic of opportunities and challenges. Western Europe tends to prioritize centralized high-complexity testing and regulatory rigor, while parts of the Middle East and Africa are rapidly expanding decentralized screening capacity and point-of-care solutions to address gaps in access. Cross-border collaborations, donor-funded initiatives, and capacity-building programs are playing pivotal roles in accelerating diagnostic availability in underserved areas throughout this combined region.

Asia-Pacific presents dynamic growth in local manufacturing, digital health integration, and public health programs that emphasize early detection. Several markets within the region are investing in both high-throughput laboratory automation and low-cost point-of-care tests to serve diverse geographies. Across all regions, variations in procurement pathways, regulatory timelines, and training resources influence adoption speed and the types of solutions that gain traction, reinforcing the need for regionally nuanced commercialization and implementation strategies.

How diagnostic manufacturers, consumable suppliers, and service providers are aligning innovation, partnerships, and operational support to strengthen the sickle cell testing value chain

Corporate behavior within the sickle cell testing ecosystem reflects a mix of platform innovation, lifecycle management, and ecosystem partnerships. Leading instrument manufacturers continue to enhance automation, throughput, and user ergonomics while extending service networks to reduce downtime and total cost of ownership for clinical laboratories. Consumable suppliers are emphasizing kit stability, streamlined workflows, and compatibility across instrument platforms to expand addressable markets and reinforce customer stickiness.

Specialized biotechnology and molecular diagnostics firms are prioritizing assay specificity and turnaround time improvements, with many pursuing collaborative arrangements with larger firms to scale distribution and regulatory access. Service providers and consultancy firms are differentiating through training, validation support, and custom assay development offerings that help clinical and research customers accelerate implementation and meet local regulatory requirements. Moreover, strategic alliances between diagnostic companies and academic or clinical centers are fostering translational pipelines that move promising assay concepts into validated, real-world use cases.

Across the competitive landscape, companies are also focusing on supply chain resilience, software-enabled services, and bundled solutions that combine instruments, consumables, and knowledge services. These integrated approaches are designed to reduce friction during procurement and implementation while providing measurable operational benefits to laboratories, hospitals, and public health programs.

Practical strategic priorities for diagnostic firms to strengthen resilience, accelerate adoption, and align innovation with clinical and operational demands in sickle cell testing

Industry leaders must adopt pragmatic, forward-looking strategies to navigate evolving clinical expectations, regulatory shifts, and supply chain uncertainties. First, prioritizing platform interoperability and modular test architectures will enable laboratories to adopt incremental upgrades without disruptive capital investments. Second, investing in regional manufacturing and diversified supplier networks can reduce exposure to trade policy changes and improve supply continuity for instruments and consumables. These measures should be complemented by robust supplier qualification processes and flexible contracting arrangements to manage procurement risk.

Third, expanding service offerings beyond traditional maintenance to include comprehensive training, validation support, and digital tools for quality assurance will differentiate providers and lower adoption barriers for end users. Fourth, engaging proactively with regulators and public health bodies to align test validation frameworks and reimbursement pathways will accelerate clinical integration and promote equitable access. Finally, companies should cultivate collaborative relationships with clinical centers and research institutions to co-develop clinically relevant assays and to generate real-world evidence that demonstrates clinical utility and operational feasibility.

By implementing these strategic priorities, industry participants can enhance resilience, accelerate responsible innovation, and deliver diagnostic solutions that meet the dual imperatives of clinical effectiveness and operational practicality across diverse healthcare environments.

Transparent multi-source research approach combining expert interviews, literature synthesis, and segmentation analysis to produce validated diagnostic market insights

The research methodology underpinning this report synthesizes multiple qualitative and quantitative sources to ensure robust, reproducible insights. Primary research includes structured interviews with laboratory directors, clinical specialists, procurement managers, and diagnostic product leaders to capture firsthand perspectives on workflow preferences, adoption barriers, and technology requirements. Secondary research leverages peer-reviewed clinical literature, regulatory guidance documents, and technology white papers to contextualize assay performance characteristics, sample handling considerations, and validation approaches.

The analytical framework integrates segmentation mapping across test types, product categories, end users, sample modalities, and channels to identify patterns of technology deployment and service needs. Regional analysis draws on policy reviews and implementation case studies to highlight regulatory and infrastructure drivers. Triangulation techniques were applied to reconcile differing inputs and to surface consensus viewpoints, while sensitivity checks were used to test the robustness of thematic findings.

Throughout the research process, emphasis was placed on methodological transparency, expert validation, and the avoidance of proprietary source dependency, ensuring that conclusions reflect a balanced synthesis of clinical, operational, and commercial perspectives relevant to stakeholders across the diagnostic ecosystem.

Synthesis of diagnostic innovation and operational resilience imperatives that together determine successful implementation and impact in sickle cell screening and testing

In conclusion, the sickle cell anemia testing landscape is characterized by simultaneous technological advancement and pragmatic implementation challenges. Molecular and high-resolution techniques are expanding the diagnostic toolkit, while improved immunoassay formats and automated systems are enhancing accessibility and throughput. At the same time, evolving trade policies, supply chain dynamics, and regional heterogeneity require adaptive commercialization and procurement strategies to ensure consistent access to high-quality testing.

For stakeholders across clinical, laboratory, and policy domains, success will depend on aligning innovation with operational realities: selecting technologies that offer the right balance of analytical performance, ease of use, and integration capability; investing in workforce training and service support; and pursuing supply chain diversification to manage external shocks. Collaborative models that link manufacturers, clinical centers, and public health programs offer a pragmatic route to scale validated solutions and to accelerate equitable access to testing across diverse care settings.

Ultimately, a cohesive approach that couples technological excellence with resilient operational design will be essential to translate diagnostic advances into measurable improvements in patient identification, clinical management, and population health outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of point-of-care neonatal screening tools in decentralized healthcare settings
  • 5.2. Adoption of high-throughput genomic sequencing workflows for early carrier detection in newborns
  • 5.3. Deployment of AI-driven pattern recognition software to differentiate sickle cell trait in screening assays
  • 5.4. Implementation of CRISPR-based molecular assays for precise detection of rare sickle cell gene variants
  • 5.5. Utilization of smartphone-enabled colorimetric assays to expand rural sickle cell screening access
  • 5.6. Expansion of mandatory newborn sickle cell screening programs across sub-Saharan African health systems
  • 5.7. Development of integrated electronic health record systems linking screening results to patient care pathways
  • 5.8. Establishment of telemedicine platforms for remote genetic counseling following positive newborn screening results
  • 5.9. Collaboration between governmental agencies and private laboratories to subsidize community sickle cell screening initiatives
  • 5.10. Introduction of multiplex immunoassay panels to enhance diagnostic throughput and reduce turnaround time in sickle cell testing

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Sickle Cell Anemia Testing & Screening Market, by Test Type

  • 8.1. High Performance Liquid Chromatography
  • 8.2. Immunoassay
    • 8.2.1. Enzyme Linked Immunosorbent Assay
    • 8.2.2. Lateral Flow
  • 8.3. Molecular Assay
    • 8.3.1. Next Generation Sequencing
    • 8.3.2. Polymerase Chain Reaction

9. Sickle Cell Anemia Testing & Screening Market, by Product

  • 9.1. Consumables
    • 9.1.1. Kits
    • 9.1.2. Reagents
  • 9.2. Instruments
    • 9.2.1. HPLC Systems
    • 9.2.2. Immunoassay Analyzers
    • 9.2.3. Molecular Diagnostic Platforms
  • 9.3. Services
    • 9.3.1. Maintenance & Support
    • 9.3.2. Training & Consultancy

10. Sickle Cell Anemia Testing & Screening Market, by End User

  • 10.1. Diagnostic Laboratories
    • 10.1.1. Hospital Based Labs
    • 10.1.2. Independent Labs
  • 10.2. Hospitals & Clinics
    • 10.2.1. Private Clinics
    • 10.2.2. Public Hospitals
  • 10.3. Research Institutes
    • 10.3.1. Academic Institutions
    • 10.3.2. Government Research Centers

11. Sickle Cell Anemia Testing & Screening Market, by Sample Type

  • 11.1. Blood Sample
    • 11.1.1. Capillary Blood
    • 11.1.2. Venous Blood
  • 11.2. Saliva Sample
    • 11.2.1. Collection Kits
    • 11.2.2. Direct Collection

12. Sickle Cell Anemia Testing & Screening Market, by Distribution Channel

  • 12.1. Direct
    • 12.1.1. Company Owned Sales Force
  • 12.2. Indirect
    • 12.2.1. Distributors
    • 12.2.2. Online Retail

13. Sickle Cell Anemia Testing & Screening Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Sickle Cell Anemia Testing & Screening Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Sickle Cell Anemia Testing & Screening Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. F. Hoffmann-La Roche Ltd
    • 16.3.2. Abbott Laboratories
    • 16.3.3. Thermo Fisher Scientific Inc.
    • 16.3.4. Bio-Rad Laboratories, Inc.
    • 16.3.5. Becton, Dickinson and Company
    • 16.3.6. Siemens Healthineers AG
    • 16.3.7. DiaSorin S.p.A.
    • 16.3.8. PerkinElmer, Inc.
    • 16.3.9. Ortho Clinical Diagnostics, Inc.
    • 16.3.10. QIAGEN N.V.

LIST OF FIGURES

  • FIGURE 1. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. SICKLE CELL ANEMIA TESTING & SCREENING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. SICKLE CELL ANEMIA TESTING & SCREENING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. SICKLE CELL ANEMIA TESTING & SCREENING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY LATERAL FLOW, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY LATERAL FLOW, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY LATERAL FLOW, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY LATERAL FLOW, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY LATERAL FLOW, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY LATERAL FLOW, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY MOLECULAR ASSAY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY MOLECULAR ASSAY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY MOLECULAR ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY MOLECULAR ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY MOLECULAR ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY MOLECULAR ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY MOLECULAR ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY MOLECULAR ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HPLC SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HPLC SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HPLC SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HPLC SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HPLC SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HPLC SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTIC PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTIC PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTIC PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTIC PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTIC PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTIC PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY MAINTENANCE & SUPPORT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY MAINTENANCE & SUPPORT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY MAINTENANCE & SUPPORT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY MAINTENANCE & SUPPORT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY MAINTENANCE & SUPPORT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY MAINTENANCE & SUPPORT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TRAINING & CONSULTANCY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TRAINING & CONSULTANCY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TRAINING & CONSULTANCY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TRAINING & CONSULTANCY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TRAINING & CONSULTANCY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TRAINING & CONSULTANCY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HOSPITAL BASED LABS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HOSPITAL BASED LABS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HOSPITAL BASED LABS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HOSPITAL BASED LABS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HOSPITAL BASED LABS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HOSPITAL BASED LABS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY INDEPENDENT LABS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY INDEPENDENT LABS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY INDEPENDENT LABS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY INDEPENDENT LABS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY INDEPENDENT LABS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY INDEPENDENT LABS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HOSPITALS & CLINICS, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PRIVATE CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PRIVATE CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PRIVATE CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PRIVATE CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY GOVERNMENT RESEARCH CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY GOVERNMENT RESEARCH CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY GOVERNMENT RESEARCH CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY GOVERNMENT RESEARCH CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY GOVERNMENT RESEARCH CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY GOVERNMENT RESEARCH CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY BLOOD SAMPLE, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY BLOOD SAMPLE, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY BLOOD SAMPLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY BLOOD SAMPLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY BLOOD SAMPLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY BLOOD SAMPLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY BLOOD SAMPLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY BLOOD SAMPLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CAPILLARY BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CAPILLARY BLOOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CAPILLARY BLOOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CAPILLARY BLOOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CAPILLARY BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CAPILLARY BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY VENOUS BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY VENOUS BLOOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY VENOUS BLOOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY VENOUS BLOOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY VENOUS BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY VENOUS BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SALIVA SAMPLE, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SALIVA SAMPLE, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SALIVA SAMPLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SALIVA SAMPLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SALIVA SAMPLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SALIVA SAMPLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SALIVA SAMPLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SALIVA SAMPLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COLLECTION KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COLLECTION KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COLLECTION KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COLLECTION KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COLLECTION KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COLLECTION KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIRECT COLLECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIRECT COLLECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIRECT COLLECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIRECT COLLECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIRECT COLLECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIRECT COLLECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIRECT, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIRECT, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIRECT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIRECT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIRECT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIRECT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIRECT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DIRECT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COMPANY OWNED SALES FORCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COMPANY OWNED SALES FORCE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COMPANY OWNED SALES FORCE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COMPANY OWNED SALES FORCE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COMPANY OWNED SALES FORCE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COMPANY OWNED SALES FORCE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY INDIRECT, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY INDIRECT, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY INDIRECT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY INDIRECT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY INDIRECT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY INDIRECT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY INDIRECT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY INDIRECT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY ONLINE RETAIL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY ONLINE RETAIL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY ONLINE RETAIL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY ONLINE RETAIL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. AM